{"doi":"10.1016/j.jtocrr.2025.100914","title":"Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes","abstract":"Introduction: tyrosine kinase inhibitors (TKIs) is unknown. Here, we characterized practice patterns and outcomes for patients who developed CNS progression during treatment with CNS-penetrable TKI. Methods: This retrospective study included patients who developed CNS progression (time 0, [T0]) on alectinib, lorlatinib, brigatinib, or ensartinib. Patients were characterized according to TKI management (i.e., TKI unaltered, TKI-altered [switched TKI or increased TKI dose], TKI discontinued) at T0. Intracranial progression-free survival was evaluated using Kaplan-Meier and compared using the log-rank test. Results: = 0.21). Conclusions: rearranged NSCLC with leptomeningeal progression or concurrent systemic progression, TKI change or dose increase was a feasible salvage strategy for CNS progression during treatment with CNS-penetrable TKI.","journal":"JTO Clinical and Research Reports","year":2025,"id":576836,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9158,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1192590,"name":"Caressa Hui","orcid":"0000-0002-3864-4720","position":1,"is_corresponding":false},{"id":32044,"name":"Joel W. Neal","orcid":"0000-0003-3119-9334","position":2,"is_corresponding":false},{"id":225608,"name":"Seema Nagpal","orcid":"0000-0002-0289-2319","position":3,"is_corresponding":false},{"id":1192591,"name":"Mohana Roy","orcid":"0000-0002-9997-8935","position":4,"is_corresponding":false},{"id":252133,"name":"Millie Das","orcid":"0000-0001-6678-9743","position":5,"is_corresponding":false},{"id":252131,"name":"Kavitha Ramchandran","orcid":"0000-0002-9033-819X","position":6,"is_corresponding":false},{"id":425399,"name":"Erqi L. Pollom","orcid":null,"position":7,"is_corresponding":false},{"id":1485668,"name":"Giovanni Selvaggi","orcid":"0000-0001-8015-8999","position":8,"is_corresponding":false},{"id":252134,"name":"Heather A. Wakelee","orcid":"0000-0003-1136-980X","position":9,"is_corresponding":false},{"id":362988,"name":"Nathaniel J. Myall","orcid":null,"position":10,"is_corresponding":false},{"id":917713,"name":"Surbhi Singhal","orcid":"0000-0003-4307-319X","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:58:00.620755Z","pmid":"41256965","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}